

6. (Amended) A retroviral vector according to claim 4 wherein the second NOI, or the expression product thereof, is or comprises a therapeutic agent or a diagnostic agent.

A2
7. (Amended) A retroviral vector according to claim 1 wherein the first NOI, or the expression product thereof, is or comprises any one or more of an agent conferring selectability (e.g. a marker element), a viral essential element, or a part thereof, or combinations thereof.

8. (Amended) A retroviral vector according to claim 1 wherein the first NS is at or near to the 3' end of a retroviral pro-vector; preferably wherein the 3' end comprises a U3 region and an R region; and preferably wherein the first NS is located between the U3 region and the R region.

A3
10. (Amended) A retroviral vector according to claim 1 wherein the first NS is obtainable from a virus.

A4
13. (Amended) A retroviral vector according to claim 1 wherein the retroviral pro-vector comprises a retroviral packaging signal; and wherein the second NS is located downstream of the retroviral packaging signal such that splicing is preventable at a primary target site.

16. (Amended) A retroviral vector according to claim 1 wherein the second NS is placed downstream of the first NOI such that the first NOI is capable of being expressed at a primary target site.

AS
17. (Amended) A retroviral vector according to claim 1 wherein the second NS is placed downstream of the first NOI such that the first NOI is capable of being expressed at a primary target site and the retroviral vector titre is enhanced.

18. (Amended) A retroviral vector according to claim 1 wherein the second NS is placed upstream of a multiple cloning site such that one or more additional NOIs may be inserted.

19. (Amended) A retroviral vector according to claim 1 wherein the second NS is a nucleotide sequence coding for an immunological molecule or a part thereof.

A6
22. (Amended) A retroviral vector according to claim 1 wherein the vector additionally comprises a functional intron.

A7
27. (Amended) A retroviral vector according to claim 1 wherein the vector or pro-vector is derivable from a murine oncoretrovirus or a lentivirus.

29. (Amended) A retroviral vector as defined in claim 1 wherein the retroviral vector is an integrated provirus.

30. (Amended) A retroviral particle obtainable from a retroviral vector according to claim 1.

31. (Amended) A cell transfected or transduced with a retroviral vector according to claim 1.

32. (Amended) A retroviral vector according to any one of claim 1.

33. (Amended) Use of a retroviral vector in claim 1 for the manufacture of a pharmaceutical composition to deliver one or more NOIs to a target site in need of same.

34. (Amended) A method comprising transfecting or transducing a cell with a retroviral vector according to claim 1.

35. (Amended) A delivery system for a retroviral vector according to claim 1 wherein the delivery system comprises one or more non-retroviral expression vector(s), adenoviruses(s), or plasmid(s) or combinations thereof for delivery of an NOI or a plurality of NOIs to a first target cell and retroviral vector for delivery of an NOI or a plurality of NOIs to a second target cell.

36. (Amended) A retroviral pro-vector as defined in claim 1.

A9
41. (Amended) Use of a hybrid viral vector system according to claim 39 wherein the lentiviral vector has a split-intron configuration.